Is Egrifta (Tesamorelin) Legal in Florida?
HealthRX.com
Egrifta is FDA-approved; Florida law does not single it out
See the public record for Tesamorelin
At a glance
- Federal status / FDA-approved prescription drug, first approved November 10, 2010 [1]
- Current labeling / Egrifta SV 2 mg vial and Egrifta WR 11.6 mg vial, once-daily subcutaneous injections [3][4]
- Approved use / Excess abdominal fat in HIV-infected adults with lipodystrophy [3]
- Not approved for / Weight loss; the label calls the effect weight neutral [3]
- FDA compounding lists / No category on the lists for state-licensed pharmacies and physicians or for outsourcing facilities [5][6]
- HHS peptide policy / Not among the six peptides in the October 2026 draft enforcement-discretion policy [7]
- Sport / WADA prohibits it at all times under S2.2.4 [8]
Does Florida change the federal answer?
FDA approval is a federal action. Egrifta was first approved on November 10, 2010 under application BLA 022505 [1]. Current prescribing information describes Egrifta SV (2 mg vial) and Egrifta WR (11.6 mg vial), both prescription-only, once-daily subcutaneous injections [3][4]. The SV dose is 1.4 mg and the WR dose is 1.28 mg, and the WR label says the two are not substitutable [3][4].
Florida's Medical Practice Act lists failing to perform a statutory or legal obligation placed on a licensed physician as grounds for disciplinary action [2]. That provision is general and does not mention tesamorelin.
Questions worth asking
What is tesamorelin approved for?
Tesamorelin is a synthetic analog of growth hormone-releasing factor (GHRH). It binds pituitary GRF receptors and prompts the pituitary to release the body's own growth hormone, which raises IGF-1 and IGFBP-3 [3]. It is a peptide, not growth hormone.
The only approved indication is reduction of excess abdominal fat in HIV-infected adults with lipodystrophy [3]. The label states that long-term cardiovascular safety has not been established, that Egrifta is not indicated for weight loss management because it has a weight neutral effect, and that there are no data showing it improves adherence to antiretroviral therapy [3].
What has FDA said about compounded tesamorelin?
Tesamorelin does not appear on FDA's page of bulk drug substances that may present significant safety risks when compounded, content dated April 22, 2026 [9]. It appears in no category on FDA's list for state-licensed pharmacies and physicians, updated May 14, 2026, or on its list for outsourcing facilities, updated March 21, 2025 [5][6]. So FDA has made no category-based statement about compounding it.
The HHS draft enforcement-discretion policy for compounded peptides, filed October 28, 2026, names six peptides: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. Tesamorelin is not one of them [7]. Compounded drugs are not FDA-approved, and FDA does not verify their safety, effectiveness or quality before they are marketed [10].
What do the labels warn about?
Neither current Egrifta label carries a boxed warning [3][4]. Contraindications are disruption of the hypothalamic-pituitary axis, active malignancy, known hypersensitivity to tesamorelin or its excipients, and pregnancy [3][4]. The label says to monitor IGF-1 during treatment; among patients treated for 26 weeks, 47% had IGF-1 above 2 SDS and 36% above 3 SDS [3]. It also reports that HbA1c of 6.5% or higher developed from baseline to week 26 in 5% of treated patients versus 1% on placebo, with a hazard ratio of about 3.3 [3]. Injection-site reactions occurred in 25% versus 14% in the first 26 weeks [3].
What about sport?
WADA names tesamorelin in S2.2.4 and prohibits it in and out of competition; it is on the 2026 List and stays on the 2027 List [8][11].
Frequently asked questions
Is Egrifta (tesamorelin) legal in Florida?
What is Egrifta approved to treat?
Is compounded tesamorelin FDA-approved?
Is tesamorelin allowed in sport?
References
Show all 11 referencesHide references
- Drugs@FDA: FDA-Approved Drugs.
- Chapter 458 Section 331 - 2023 Florida Statutes - The Florida Senate.
- U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
- U.S. National Library of Medicine, DailyMed. Egrifta WR (tesamorelin) for injection, 11.6 mg vial prescribing information. Egrifta WR (tesamorelin) for injection, 11.6 mg vial label
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Official web page.
- World Anti-Doping Agency.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- Compounding and the FDA: Questions and Answers | FDA.
- World Anti-Doping Agency.